恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600276 恒瑞医药

交易中 01-07 10:41:34

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":64.56,"timestamp":1767753694000,"preClose":63.06,"halted":0,"volume":27311263,"delay":0,"changeRate":0.0238,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"交易中","change":1.5,"latestTime":"01-07 10:41:34","open":63.01,"high":64.8,"low":63,"amount":1754000000,"amplitude":0.0285,"askPrice":64.54,"askSize":18,"bidPrice":64.53,"bidSize":7,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1767756600000},"marketStatusCode":2,"adr":0,"adjPreClose":63.06,"symbolType":"stock","openAndCloseTimeList":[[1767749400000,1767756600000],[1767762000000,1767769200000]],"highLimit":69.37,"lowLimit":56.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":7.03,"roa":"--","peRate":57.376466,"roe":"11.09%","epsLYR":1,"committee":-0.542056,"marketValue":428497999999.9999,"turnoverRate":0.0043,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":77.95,"timestamp":1767753693654,"preClose":74.55,"halted":0,"volume":1651866,"delay":0,"premium":"+8.30"},"floatMarketCap":411828000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2601685608","title":"恒瑞医药2025年12月股份变动：A股员工持股计划致总股本微增","url":"https://stock-news.laohu8.com/highlight/detail?id=2601685608","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601685608?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:52","pubTimestamp":1767671537,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司于2026年1月5日发布了截至2025年12月31日的证券变动月报表。报告显示，公司总股本在报告期内略有增加。此次A股股份的增加，源于公司根据其2022年、2023年、2024年及2025年A股员工持股计划进行的股份授予或归属，本月内因此新增发行了3,738,950股A股。本次变动后，江苏恒瑞医药的总已发行股份数达到6,637,199,874股。公司库存股份数量在本月内未发生变动，A股和H股的库存股份数均为零。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2148510915.USD","BK0012","LU1064130708.USD","LU1781817850.SGD","LU2097828714.EUR","LU1580142542.USD","LU1969619763.USD","LU2580892862.HKD","LU0405327494.USD","LU2289578879.USD","LU2543165471.USD","LU2488822045.USD","LU0405327148.USD","BK0239","BK0183","LU0359202008.SGD","LU2580892789.USD","BK0060","BK0196","399300","LU0359201885.HKD","LU1997245177.USD","LU2097828474.EUR","LU1255011170.USD","LU2097828631.EUR","LU1997244956.HKD","LU2097828805.USD","159982","LU1146622755.USD","LU2097828557.USD","LU1820825898.SGD","LU2495084118.USD","BK1191","BK0188","LU1023057109.AUD","01276","BK0028","LU1328615791.USD","LU1997245094.SGD","LU2328871848.SGD","LU0359201612.USD","LU1655091616.SGD","LU1064131003.USD","600276"],"gpt_icon":0},{"id":"2601004192","title":"恒瑞医药：子公司收到药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601004192","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601004192?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:09","pubTimestamp":1767604169,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月5日，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于HRS-4357注射液、HRS-5041片的《药物临床试验批准通知书》，同意开展临床试验。具体为：HRS-4357联合HRS-5041用于PSMA阳性前列腺癌治疗的安全性、耐受性及初步疗效的开放、多中心、Ib/II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608869671.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608869671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2289578879.USD","LU1580142542.USD","BK0060","LU0405327494.USD","LU1997244956.HKD","LU1064130708.USD","LU1255011170.USD","LU2580892789.USD","BK0196","LU1969619763.USD","LU2097828474.EUR","LU0359202008.SGD","LU2097828557.USD","BK0239","LU2097828805.USD","LU2488822045.USD","LU0405327148.USD","LU1781817850.SGD","LU1064131003.USD","LU1655091616.SGD","BK0028","LU1997245094.SGD","LU1820825898.SGD","LU1997245177.USD","LU2495084118.USD","LU1023057109.AUD","600276","BK0012","BK1191","LU0359201612.USD","LU1328615791.USD","LU2328871848.SGD","LU2097828631.EUR","LU2543165471.USD","BK0183","LU2580892862.HKD","LU0359201885.HKD","LU2148510915.USD","LU1146622755.USD","LU2097828714.EUR","BK0188","01276"],"gpt_icon":0},{"id":"2600152047","title":"恒瑞医药(01276)截至12月末累计回购A股股份889.87万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2600152047","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600152047?lang=zh_cn&edition=full","pubTime":"2026-01-04 18:48","pubTimestamp":1767523708,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，2025年12月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份0股。截至2025年12月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份889.87万股，已回购股份占公司总股本的比例为0.13%，购买的最高价为人民币70.00元/股，最低价为人民币59.32元/股，已支付的总金额为人民币59,521.63万元(不含交易费用)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","LU2580892862.HKD","LU2495084118.USD","BK0196","LU1023057109.AUD","LU1064130708.USD","LU2097828557.USD","BK0028","159982","LU1255011170.USD","LU2543165471.USD","LU1146622755.USD","LU1580142542.USD","BK0183","LU1997244956.HKD","600276","LU1328615791.USD","LU2097828714.EUR","LU1997245094.SGD","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","LU0359201885.HKD","LU2097828631.EUR","399300","BK0012","LU0405327148.USD","BK0060","01276","BK0239","BK0188","LU2328871848.SGD","LU2580892789.USD","LU0359201612.USD","BK1191","LU2097828474.EUR","LU0359202008.SGD","LU1820825898.SGD","LU1655091616.SGD","LU0405327494.USD","LU2289578879.USD","LU2097828805.USD"],"gpt_icon":0},{"id":"2600054319","title":"智通AH统计|1月2日","url":"https://stock-news.laohu8.com/highlight/detail?id=2600054319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600054319?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:15","pubTimestamp":1767341704,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月2日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为847.37%、398.38%、286.02%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-14.50%、-5.83%、-3.71%。其中浙江世宝、广和通、中船防务的偏离值位居前三，分别为86.11%、17.07%、11.89%；另外，东北电气、新华保险、广汽集团的偏离值位居后三，分别为-40.60%、-13.42%、-13.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03143","LU0173614495.USD","LU0823426480.USD","LU1251922891.USD","BK1191","LU2399975544.HKD","LU0048580855.USD","BK1523","LU0348814723.USD","BK1179","BK1614","BK1576","LU1282649067.USD","IE0008368742.USD","LU0214875030.USD","LU1242518931.SGD","BK1129","LU0862451753.SGD","LU0359201885.HKD","LU0328353924.USD","BK1183","BK1105","IE00BZ08YR35.GBP","LU1808992512.USD","LU0359202008.SGD","LU1328277881.USD","IE00BZ08YT58.USD","LU0449515922.USD","LU1226287529.USD","LU1366334578.USD","LU1211504680.USD","LU0543330566.HKD","LU0868486357.SGD","LU1769817179.HKD","BK1564","IE0034224299.USD","LU0488056044.USD","LU0979878070.USD","LU1770034418.SGD","HK0000500386.USD","BK1144","LU2097828631.EUR","IE00B031J352.USD","LU0516422952.EUR","HK0000252160.HKD","LU0266512473.USD","LU1115378108.SGD","LU2543165471.USD","BK1507","IE00BGHQDM52.EUR","BK1546","IE00B031HY20.USD","BK1198","LU0264606111.USD","LU1008478684.HKD","002703","LU1481107354.HKD","IE00B543WZ88.USD","LU2039709279.SGD","BK1506","LU0648948544.HKD","LU0463099449.HKD","LU0737861699.HKD","BK1594","LU1961090484.USD","LU0315179316.USD","BK1184","LU0348816934.USD","IE00B29SXG58.USD","LU1366334651.USD","LU0823426308.USD","LU0918141887.USD","LU0320764599.SGD","LU0345780281.USD","LU0307460666.USD","LU0516423091.SGD","BK1539","IE00BVYPNQ40.USD","LU0072913022.USD","01057","SG9999014674.SGD","HK0000320264.USD","LU0455707207.USD","LU0211977185.USD","LU0149721374.USD","LU0572940350.SGD","LU1282649141.HKD","BK1202","LU0469268626.HKD","HK0000320223.HKD","LU0181495838.USD","LU0266512127.USD","BK1119","LU0164880469.USD","LU0061477393.USD","LU0106252389.USD","LU0384037296.USD","SG9999003461.SGD","LU0228659784.USD","LU1807302812.USD","SG9999004220.SGD","LU1960683339.HKD","BK1514","BK1550","LU0117841782.USD","LU0345780521.USD","LU1880383440.USD","LU0572939691.SGD","00042","BK1173","LU0516422366.SGD","LU0737861772.HKD","LU0329678170.USD","IE00BYV24P56.USD","LU1880383366.USD","BK1116","LU0821914370.USD","LU2226246903.HKD","600036","LU0640798160.USD","LU0417516738.SGD","BK1509","BK1515","LU0229945570.USD","BK1554","LU0254981946.USD","BK1560","LU0501845795.SGD","LU0228367735.SGD","LU0348825331.USD","SG9999002463.SGD","LU0054450605.USD","LU0359201612.USD","LU1046422090.SGD","LU0348788117.USD","BK1231","LU0370786039.SGD","LU1769817096.USD","IE00B0169L03.USD","LU0287142896.SGD","LU0051755006.USD","BK1551","LU0163747925.USD","LU0417516902.SGD","LU0588546209.SGD","BK1535","LU0449509016.USD","LU2097828557.USD","LU0502904849.HKD","LU2476274720.SGD","BK1562","LU0456827905.SGD","SG9999001226.SGD","001236","BK1544","LU1504937902.USD","IE00BF5LJ272.USD","600276","BK1223","HK0000306701.USD","159982","LU0561508036.HKD","LU0164865239.USD","LU0456846285.SGD","LU0052750758.USD","LU0880133367.SGD","399300","LU0456854461.SGD","LU1152091168.USD","LU0348805143.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1141","LU2045819591.USD","LU0431992006.USD","IE00B3M56506.USD","LU0140636845.USD","LU0572944931.SGD","LU1794554557.SGD","BK1521","LU0890818403.SGD","LU0106959298.USD","LU2097828805.USD","LU0067412154.USD","LU0791591158.USD","LU0049853897.USD","LU0828237510.HKD","LU0231483743.USD","LU0797268264.HKD","LU1675838814.USD","LU0096374516.USD","BK1526","LU1188198961.HKD","BK1214","LU0886674414.USD","BK1584","LU1303224171.USD","LU0791590937.USD","LU0918141705.HKD","LU1813983027.USD","BK1124","LU0531970944.HKD","LU0540923850.HKD","LU1282648689.USD","LU0516422440.USD","LU2778985437.USD","IE0008369823.USD","LU0589944569.HKD","HK0000306685.HKD","BK1522","BK1610","LU1282649810.SGD","LU2242644610.SGD","LU2097828714.EUR","LU0244354667.USD","LU1242518857.USD","03678","BK1583","BK1505","LU0327786744.USD","CIHKY","LU2476274308.USD","LU0593848301.USD","LU2097828474.EUR","BK1171","LU0531971595.HKD","LU0516423174.USD","LU1105468828.SGD","LU1831875114.USD","BK1205","BK1592","01276","LU0039217434.USD","LU1023057109.AUD","SG9999002828.SGD","LU1993786604.SGD","LU0348827113.USD","LU1152091754.HKD","03968","LU0871576103.HKD","LU1048596156.SGD","IE00BMCWC346.EUR","LU1224709979.USD","BK1163","BK1190","LU0326950275.SGD","LU0329678337.USD","LU0314109678.HKD","LU0708995583.HKD","LU1720050803.USD","BK1237","LU0828237940.HKD","300750","LU1688375341.USD","BK1558","IE0031814852.USD","HK0000252152.HKD","LU1719994722.HKD","SG9999006597.SGD","BK1154","BK1147","BK1607","IE00BVYPNP33.GBP","LU0823040885.USD","IE00BZ08YS42.EUR","LU2125910500.SGD","BK1149","LU0348735423.USD"],"gpt_icon":1},{"id":"2600056352","title":"港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2600056352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600056352?lang=zh_cn&edition=full","pubTime":"2026-01-02 13:43","pubTimestamp":1767332632,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2的抗体药物偶联物——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK4080","LU2488822045.USD","LU2289578879.USD","LU1781817850.SGD","BK0012","BK0196","LU1820825898.SGD","LU2580892789.USD","LU0359201885.HKD","BK0239","LU2580892862.HKD","LU2328871848.SGD","BK0188","LU2097828631.EUR","LU1023057109.AUD","BK4231","LU1580142542.USD","LU1997245094.SGD","BK0028","LU0359201612.USD","LU1146622755.USD","LU1655091616.SGD","LU2097828557.USD","LU0359202008.SGD","LU1328615791.USD","LU1997244956.HKD","LU1997245177.USD","BK0183","600276","LU2148510915.USD","LU1255011170.USD","LU1064130708.USD","LU2097828805.USD","BK1191","LU1969619763.USD","LU2097828474.EUR","LU2543165471.USD","01276","LU0405327494.USD","LU2495084118.USD","ADC","LU0405327148.USD","LU2097828714.EUR","LU1064131003.USD"],"gpt_icon":0},{"id":"2595792596","title":"恒瑞医药六款创新药获临床试验批件，肿瘤管线再扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792596","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595792596?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:26","pubTimestamp":1767097566,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司及其子公司近日宣布，其自主研发及引进的六款抗肿瘤新药已获得国家药品监督管理局颁发的药物临床试验批准通知书，即将进入临床研究阶段。此次获批的药品包括SHR-4375注射液、阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、HRS-4642注射液及注射用SHR-9839，将联合开展一项针对晚期实体肿瘤患者的Ib/II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31904557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1781817850.SGD","LU2543165471.USD","BK1191","LU1255011170.USD","LU1655091616.SGD","BK0239","LU1820825898.SGD","LU2488822045.USD","LU1023057109.AUD","LU2289578879.USD","LU1969619763.USD","BK0012","LU2580892789.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","01276","LU1064131003.USD","LU2097828474.EUR","LU1997245177.USD","BK0183","600276","LU1328615791.USD","LU0405327494.USD","LU0405327148.USD","LU0359201612.USD","LU2097828557.USD","LU2097828714.EUR","BK1161","06978","159992","LU1064130708.USD","LU2097828631.EUR","LU1146622755.USD","BK0028","BK0188","BK0060","LU2328871848.SGD","LU0359201885.HKD","LU1580142542.USD","LU1997245094.SGD","BK0196","LU1997244956.HKD","BK1574","LU0359202008.SGD"],"gpt_icon":0},{"id":"2595782399","title":"恒瑞医药SHR-4375注射液等6款药品临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2595782399","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595782399?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:16","pubTimestamp":1767006961,"startTime":"0","endTime":"0","summary":"北京商报讯12月29日，恒瑞医药发布公告称，公司及子公司上海恒瑞医药有限公司、上海盛迪医药有限公司、苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-4375注射液、阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、HRS-4642注射液、注射用SHR-9839（sc）的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512293604578310.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604578310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","BK0183","LU1255011170.USD","BK1191","LU1820825898.SGD","LU0405327494.USD","01276","LU1969619763.USD","LU1997245177.USD","600276","BK0196","LU2543165471.USD","LU2097828474.EUR","LU2097828631.EUR","LU0359202008.SGD","LU2580892789.USD","BK0028","LU1997244956.HKD","LU1023057109.AUD","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU0405327148.USD","LU2495084118.USD","LU1580142542.USD","LU2097828805.USD","LU1064131003.USD","LU1146622755.USD","LU1328615791.USD","LU0359201612.USD","LU1781817850.SGD","BK0060","LU1064130708.USD","LU2580892862.HKD","BK0012","LU0359201885.HKD","LU2289578879.USD","LU2328871848.SGD","LU2148510915.USD","BK0188","BK0239","LU1655091616.SGD"],"gpt_icon":0},{"id":"2595781654","title":"智通港股空仓持单统计|12月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2595781654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595781654?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:30","pubTimestamp":1767004204,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月19日，未平仓空单比位列前三位为万科企业、中远海控、恒瑞医药，空仓比分别为18.48%、16.79%、15.54%。未平仓空单比（绝对值）较上一次增加最多为宁德时代、蓝思科技、优必选，分别增加2.35%、2.34%、1.29%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1546","LU0348784397.USD","BK1589","LU0488056044.USD","BK1604","LU2045819591.USD","LU0588545904.SGD","LU0348827113.USD","LU0196878994.USD","601318","601919","BK1619","LU1044874839.SGD","LU0791591158.USD","LU0359201612.USD","BK1170","IE00BMCWC346.EUR","LU2153592121.USD","LU0417516571.SGD","LU0348825331.USD","LU0865486749.SGD","00357","LU1048588211.SGD","LU1235295612.USD","IE00BZ08YR35.GBP","LU0384037296.USD","BK1168","BK1147","IE00BVYPNQ40.USD","LU2097828631.EUR","LU1719994722.HKD","HK0000252152.HKD","LU0501845795.SGD","LU0266512127.USD","BK1618","LU1105468828.SGD","LU1497734951.SGD","BK1183","LU0540923850.HKD","LU1960683339.HKD","LU0737861772.HKD","LU2476274720.SGD","LU1497733557.USD","LU0469268626.HKD","LU1981816686.USD","LU0417516738.SGD","LU0821914370.USD","LU0287142896.SGD","LU0051755006.USD","LU0828237510.HKD","BK1131","LU0531971595.HKD","LU0348783662.USD","LU0762540952.USD","LU0328353924.USD","LU0878005551.USD","LU0456827905.SGD","LU1303224171.USD","LU1211504680.USD","LU2242644610.SGD","HK0000320264.USD","LU1051769294.HKD","IE0003895053.USD","LU1481107354.HKD","LU0605514214.HKD","LU0819121731.USD","601869","IE00BZ08YS42.EUR","LU0049112450.USD","LU1831875114.USD","BK1240","BK1529","LU2476274308.USD","LU0163747925.USD","LU1769817179.HKD","LU0320764599.SGD","LU1642822792.SGD","LU0348766576.USD","LU0314109678.HKD","LU0096374516.USD","LU2399975544.HKD","HK0000306701.USD","LU0061477393.USD","LU0463099449.HKD","LU2097828474.EUR","SG9999004220.SGD","LU1366334651.USD","BK1503","LU1961090484.USD","LU0348816934.USD","LU0348788117.USD","LU0588545490.SGD","IE0034224299.USD","LU2097828714.EUR","LU1720050803.USD","IE0008368742.USD","BK1135","BK1544","LU0561508036.HKD","LU0106252389.USD","LU0348735423.USD","PNGAY","LU0140636845.USD","80020","LU0588545730.USD","SG9999002562.SGD","LU0572944931.SGD","LU1366334578.USD","BK1149","BK1563","IE00BF5LJ272.USD","LU0359201885.HKD","BK1184","LU1226287529.USD","LU1522347837.USD","600276","BK1594","BK1554","BK1523","LU0072462343.USD","SG9999001093.SGD","LU0651946864.USD","LU0819123356.HKD","LU1282649141.HKD","LU2125910500.SGD","SG9999001051.SGD","LU0084288322.USD","SG9999001069.SGD","LU0737861699.HKD","82318","BK1521","LU1224709979.USD","LU1634259557.SGD","BK1613","LU0235996351.USD","01919","LU0630378429.USD","LU0762541174.USD","LU0054450605.USD","LU1044876610.USD","LU0345780521.USD","BK1501","BK1535","LU0052750758.USD","LU0648948544.HKD","BK1507","BK1587","LU0370786039.SGD","BK1188","LU1188198961.HKD","LU0348805143.USD","BK1228","LU0244354667.USD","LU2488822045.USD","BK1104","LU1152091168.USD","LU0326950275.SGD","LU0878004406.USD","LU0640798160.USD","01318","LU1115378108.SGD","BK1141","LU0293314216.USD","LU1770034418.SGD","LU0456854461.SGD","LU0106959298.USD","LU0348814723.USD","BK1564","LU2543165471.USD","SG9999004311.SGD","BK1169","LU0173614495.USD","300433","BK1550","HK0000320223.HKD","SG9999006597.SGD","BK1516","LU2293587155.HKD","HPAD.SI","BK1207","LU1880383366.USD","LU1808992512.USD","LU1023057109.AUD","LU1242518857.USD","LU1504937902.USD","IE00BVYPNP33.GBP","LU0651947912.USD","LU1048596156.SGD","HK0000252160.HKD","LU0856984785.SGD","LU0164880469.USD","LU2778985437.USD","LU0164872284.USD","LU0449515922.USD","BK1095","BK1196","LU0828237940.HKD","BK1608","LU0611395673.USD","LU0880133367.SGD","LU1051768304.USD","LU0650527681.SGD","LU1813983027.USD","IE00BZ08YT58.USD","LU1251922891.USD","BK1198","SG9999002463.SGD","LU0049853897.USD","02202","BK1555","LU1044875133.USD","LU1224444064.USD","LU1794554557.SGD","LU0348767384.USD","01276","LU0630378692.HKD","LU1328277881.USD","LU2039709279.SGD","LU0890818403.SGD","LU0327786744.USD","BK1588","LU0918141705.HKD","LU0181495838.USD","SG9999003461.SGD","BK1109","BK1515","LU1046422090.SGD","LU1497733631.SGD","LU0594300419.USD","000002","SG9999001440.SGD","BK1615","LU1807302812.USD","03145","LU0791590937.USD","LU1769817096.USD","LU0067412154.USD","PAImain","LU1282649067.USD","LU2097828805.USD","LU0164865239.USD","LU0762542818.HKD","LU0708995583.HKD","06613","SG9999014674.SGD","BK1610","LU2348774022.SGD","HK0000500386.USD","HK0000306685.HKD","LU1152091754.HKD","LU1282649810.SGD","BK1576","LU0039217434.USD","LU0345780281.USD","LU0823426308.USD","LU1634259391.SGD","LU0149721374.USD","LU0417516902.SGD","BK1575","LU0797268264.HKD","BK1561","IE00BYV24P56.USD","BK1103","BK1504","BK1506","LU0197773160.USD","LU1515016050.SGD","BK1592","LU0329678337.USD","LU0329678170.USD","BK1116","LU1282651121.HKD","LU0588546209.SGD","LU0315179316.USD","LU0862451753.SGD","BK1556","BK1205","BK1505","LU0197773673.USD","LU1880383440.USD","LU0348783233.USD","LU0594300179.USD","LU1282651048.USD","BK1595","LU0315178854.USD","LU1008478684.HKD","LU0886674414.USD","IE00B29SXG58.USD","IE00BGHQDM52.EUR","LU0307460666.USD","LU0254981946.USD","LU0359202008.SGD","BK1522","LU1675838814.USD","BK1526","LU0918141887.USD","LU0165289439.USD","LU0979878070.USD","LU1993786604.SGD","LU0048580855.USD","LU0634319403.HKD","LU0871576103.HKD","03750","LU0266512473.USD","LU0043850808.USD","LU0882747503.HKD","LU1282648689.USD","LU2097828557.USD","SG9999002828.SGD","BK1583","BK1612","BK1127","LU0072913022.USD","LU0211977185.USD","300750","LU0228367735.SGD","BK1161","LU2226246903.HKD","LU0823426480.USD","BK1607","BK1191","LU1242518931.SGD","LU0228659784.USD","LU0831093199.SGD"],"gpt_icon":1},{"id":"2594822143","title":"恒瑞医药(600276.SH)与翰森制药签署SHR6508项目独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2594822143","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594822143?lang=zh_cn&edition=full","pubTime":"2025-12-28 16:43","pubTimestamp":1766911410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公告，公司与翰森制药集团有限公司签署《独家许可协议》，将公司SHR6508项目有偿许可给翰森制药;公司子公司成都盛迪医药有限公司与翰森制药子公司江苏豪森药业集团有限公司签署《商业化服务框架协议》，委托豪森药业为公司帕立骨化醇软胶囊产品提供非独家商业化服务。公司帕立骨化醇软胶囊于2025年11月获得国家药监局批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","LU2097828805.USD","LU1580142542.USD","LU0359202008.SGD","LU2495084118.USD","LU1023057109.AUD","600276","LU0405327494.USD","LU1255011170.USD","LU1969619763.USD","BK0183","LU1146622755.USD","LU2097828714.EUR","BK1583","LU1820825898.SGD","BK0239","BK0196","LU1997244956.HKD","LU2488822045.USD","LU2148510915.USD","LU2580892862.HKD","LU2097828474.EUR","LU2328871848.SGD","LU1781817850.SGD","03692","LU1655091616.SGD","LU0405327148.USD","LU2289578879.USD","LU0359201612.USD","BK0012","BK0028","LU2543165471.USD","LU1997245094.SGD","BK0060","LU0359201885.HKD","LU1997245177.USD","LU1328615791.USD","01276","LU1064130708.USD","LU2097828631.EUR","LU2580892789.USD","LU1064131003.USD","BK0188","LU2097828557.USD","BK1191"],"gpt_icon":0},{"id":"2594610296","title":"恒瑞医药：预计2026年3月26日公布年报，预测Q4一致预期营收320.72~360.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594610296","media":"朝阳永续","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594610296?lang=zh_cn&edition=full","pubTime":"2025-12-26 19:01","pubTimestamp":1766746860,"startTime":"0","endTime":"0","summary":"截至2025年12月26日，根据朝阳永续季度业绩前瞻数据：预测公司Q4一致预期营业收入320.72~360.62亿元，同比增长14.6%~28.9%；预测公司Q4一致预期净利润78.82~100.96亿元，同比增长24.4%~59.3%。在业务发展方面，恒瑞医药在对外授权合作上取得显著成果，与GSK、Glenmark和Braveheart_Bio等公司达成合作，涉及药物首付款总计5.83亿美元，里程碑付款最高可达141.16亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecrxk0904902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600276","01276"],"gpt_icon":0},{"id":"2594622922","title":"智通AH统计|12月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2594622922","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594622922?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:15","pubTimestamp":1766736905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月26日收盘，东北电气、浙江世宝、钧达股份分列AH溢价率前三位，溢价率分别为900.00%、472.95%、286.59%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-11.39%、-3.20%、2.72%。其中浙江世宝、钧达股份、南京熊猫电子股份的偏离值位居前三，分别为187.01%、94.84%、36.09%；另外，广汽集团、长飞光纤光缆、北京北辰实业股份的偏离值位居后三，分别为-22.30%、-19.89%、-10.98%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1560","LU0327786744.USD","SG9999002463.SGD","LU0456827905.SGD","IE00B5MMRT66.SGD","LU1242518857.USD","LU0572939691.SGD","LU1961090484.USD","LU0593848301.USD","LU1048596156.SGD","BK1551","LU0431992006.USD","LU0972618739.USD","LU0345780281.USD","LU0561508036.HKD","03968","IE00BVYPNP33.GBP","LU0463099449.HKD","LU0149721374.USD","LU0164865239.USD","LU2778985437.USD","SG9999002950.SGD","LU0054450605.USD","LU1023057109.AUD","LU0164880469.USD","LU1688375341.USD","CIHKY","LU1880383440.USD","BK1184","LU0328353924.USD","LU0918141705.HKD","IE00BZ18W456.USD","002703","LU0828237510.HKD","SG9999006597.SGD","LU0370786039.SGD","BK1583","LU0572944931.SGD","LU0918141887.USD","LU2476274308.USD","BK1544","LU0737861699.HKD","IE00BZ08YR35.GBP","LU1655091616.SGD","LU2097828805.USD","LU0231483743.USD","LU0640798160.USD","LU0228367735.SGD","BK1564","LU0540923850.HKD","BK1206","LU0214875030.USD","LU0531971595.HKD","LU0634319403.HKD","HK0000252160.HKD","LU1303224171.USD","LU1769817179.HKD","LU1770034418.SGD","LU0359201885.HKD","BK1183","BK1202","LU1008478684.HKD","LU2399975544.HKD","LU1785774172.SGD","SG9999014674.SGD","IE00B031J352.USD","LU0543330566.HKD","LU0589944569.HKD","LU2039709279.SGD","LU0254981946.USD","LU1813983027.USD","IE00B29SXG58.USD","LU0886674414.USD","LU0314109678.HKD","LU0890818403.SGD","LU0979878070.USD","BK1523","BK1576","LU1188198961.HKD","BK1147","LU0229945570.USD","LU1046422090.SGD","BK1568","BK1550","LU0348825331.USD","LU0791591158.USD","LU0469268626.HKD","BK1205","LU0348735423.USD","LU0449509016.USD","BK1198","IE00BMQBXF63.USD","LU0455707207.USD","BK1240","LU1226287529.USD","IE00B031HY20.USD","LU1282648689.USD","BK1506","LU1211504680.USD","LU0049853897.USD","BK1141","LU1993786604.SGD","BK1513","BK1539","LU0417516902.SGD","LU0264606111.USD","LU0266512473.USD","LU2097828557.USD","BK1214","IE0031814852.USD","BK1191","LU0039217434.USD","BK1237","LU0737861772.HKD","LU1115378108.SGD","LU2476274720.SGD","601869","LU0211977185.USD","SG9999004220.SGD","LU0456854461.SGD","BK1509","IE00BZ18W340.USD","IE00B543WZ88.USD","LU0269904917.USD","LU0516422952.EUR","BK1562","LU0096374516.USD","BK1223","LU0329678337.USD","LU1251922891.USD","LU2543165471.USD","BK1535","LU0516423091.SGD","LU1152091754.HKD","LU0348816934.USD","LU0501845795.SGD","BK1173","LU0106959298.USD","LU0359201612.USD","LU0871576103.HKD","LU0051755006.USD","IE0008369823.USD","HK0000320264.USD","LU0502904849.HKD","LU0348814723.USD","LU1224709979.USD","LU2242644610.SGD","LU1719994722.HKD","SG9999002828.SGD","LU1720050803.USD","BK1149","BK1129","01057","IE00BMCWC346.EUR","LU0405327148.USD","HK0000320223.HKD","LU0509642566.USD","LU0868486357.SGD","IE00BVYPNQ40.USD","LU0449515922.USD","LU0823426480.USD","LU0052750758.USD","BK1116","LU0067412154.USD","LU0823040885.USD","LU0572940350.SGD","LU1282649067.USD","BK1592","00553","LU0791590937.USD","03750","LU0348805143.USD","00588","LU0488056044.USD","LU1769817096.USD","LU1807302812.USD","LU2097828631.EUR","LU0329678170.USD","600036","LU0359202008.SGD","LU0823426308.USD","LU1481107354.HKD","LU2226246903.HKD","LU2125910500.SGD","LU1282649810.SGD","BK1521","LU0173614495.USD","BK1584","LU2097828714.EUR","BK1154","BK1546","LU0738912210.USD","IE00BZ08YS42.EUR","BK1554","600276","LU1880383366.USD","LU0326950275.SGD","IE00B3M56506.USD","00042","LU0315179316.USD","LU0880133367.SGD","BK1163","IE00BF5LJ272.USD","BK1610","LU1328277881.USD","LU2097828474.EUR","LU0828237940.HKD","IE00BZ08YT58.USD","BK1558","IE00B0169L03.USD","LU1105468828.SGD","LU1960683339.HKD","LU0516423174.USD","LU0348827113.USD","LU0648948544.HKD","LU0516422440.USD","BK1119","LU0287142896.SGD","LU0821914370.USD","IE0034224299.USD","BK1522","BK1144","HK0000306685.HKD","IE00BYV24P56.USD","LU0405327494.USD","LU1282649141.HKD","601238","03143","LU1675838814.USD","BK1594","02865","BK1505","LU0320764599.SGD","LU0456846285.SGD","LU0345780521.USD","LU0588546209.SGD","LU0797268264.HKD","LU1808992512.USD","02238","BK1514","LU0531970944.HKD","01276","HK0000252152.HKD","LU0117841782.USD","HK0000306701.USD","LU1366334651.USD","LU0417516738.SGD","LU1794554557.SGD","LU0414403682.SGD","LU0828238088.HKD","LU1242518931.SGD","LU1831875114.USD","LU0140636845.USD","600775","BK1185","LU0244354667.USD","LU0307460666.USD","LU0384037296.USD","LU0708995583.HKD","601588","BK1231","LU0072913022.USD","LU0048580855.USD","LU1152091168.USD","LU1504937902.USD","300750","IE00BGHQDM52.EUR","LU0163747925.USD","LU0106252389.USD","LU0516422366.SGD","IE0008368742.USD","LU1366334578.USD","LU0266512127.USD","BK1507","LU0181495838.USD","LU0862451753.SGD","HK0000500386.USD","LU0061477393.USD","BK1567","LU2045819591.USD","BK1171","LU0228659784.USD","LU0348788117.USD"],"gpt_icon":1},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","BK0183","02096","09995","LU0405327494.USD","002755","LU1969619763.USD","01167","LU1997245177.USD","02142","600276","BK1161","BK0196","603087","688062","LU2097828474.EUR","01801","LU2097828631.EUR","000661","BK0028","LU1997244956.HKD","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU0405327148.USD","LU2495084118.USD","LU2097828805.USD","LU1064131003.USD","LU1146622755.USD","688336","LU1328615791.USD","LU1781817850.SGD","688331","03692","BK1593","BK1589","BK0057","BK0060","LU1064130708.USD","LU2580892862.HKD","BK0012","BK1574","01530","LU2148510915.USD","06978","BK0188","BK0239","LU0502904849.HKD","02509","688428"],"gpt_icon":0},{"id":"2593475884","title":"恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475884","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475884?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:37","pubTimestamp":1766569070,"startTime":"0","endTime":"0","summary":"12月24日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司近日获得国家药品监督管理局核准签发的关于注射用SHR-A2102的《药物临床试验批准通知书》，将于近期开展临床试验。该药物为公司自主研发的靶向Nectin-4的抗体药物偶联物，具有知识产权，其有效载荷是拓扑异构酶Ⅰ抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600814636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU2488822045.USD","LU1064130708.USD","LU2097828557.USD","LU1820825898.SGD","LU2148510915.USD","LU1997245177.USD","LU1969619763.USD","LU1781817850.SGD","LU0405327148.USD","LU0405327494.USD","LU2580892862.HKD","BK0196","BK0239","LU1997245094.SGD","01276","LU1997244956.HKD","LU2289578879.USD","600276","LU0359201885.HKD","LU1146622755.USD","LU1255011170.USD","BK0028","LU2580892789.USD","BK0012","LU2097828474.EUR","LU0359201612.USD","LU2097828631.EUR","LU2328871848.SGD","LU2097828805.USD","LU1064131003.USD","BK0188","BK0060","LU2097828714.EUR","LU2543165471.USD","LU1023057109.AUD","LU1655091616.SGD","LU2495084118.USD","LU1328615791.USD","LU1580142542.USD","LU0359202008.SGD","BK0183"],"gpt_icon":1},{"id":"2593478682","title":"恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593478682?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:54","pubTimestamp":1766566481,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日,公司及子公司上海恒瑞医药有限公司注射用SHR-A1904被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。该药品拟定适应症(或功能主治)：既往接受至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU2097828714.EUR","BK0012","LU1023057109.AUD","01276","LU1997245094.SGD","LU1997245177.USD","LU2543165471.USD","LU2097828474.EUR","LU2488822045.USD","LU2148510915.USD","LU1064130708.USD","LU2495084118.USD","LU2097828805.USD","LU2328871848.SGD","LU1580142542.USD","600276","BK0239","LU1064131003.USD","LU2580892789.USD","LU1146622755.USD","LU2580892862.HKD","BK0196","LU1655091616.SGD","LU0359202008.SGD","BK0028","LU1328615791.USD","LU1781817850.SGD","LU2097828631.EUR","LU1255011170.USD","BK0188","LU1820825898.SGD","BK1191","LU2097828557.USD","LU1969619763.USD","LU0359201612.USD","LU0405327148.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2593945147","title":"恒瑞医药祝您暖意相随，喜乐常安！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593945147","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593945147?lang=zh_cn&edition=full","pubTime":"2025-12-21 07:00","pubTimestamp":1766271600,"startTime":"0","endTime":"0","summary":"往期精选| 研发创新|| 国际化|| 重磅奖项|| 社会公益| ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251221/c673379626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2097828714.EUR","LU1969619763.USD","LU2148510915.USD","LU1064131003.USD","LU1255011170.USD","600276","LU2097828631.EUR","LU1997245094.SGD","LU2097828557.USD","LU1064130708.USD","LU1580142542.USD","LU2289578879.USD","LU2495084118.USD","LU1997245177.USD","BK0183","LU1655091616.SGD","LU0405327148.USD","LU2580892789.USD","BK0028","LU2097828474.EUR","LU2488822045.USD","BK0196","LU1781817850.SGD","LU1328615791.USD","BK0012","LU1820825898.SGD","BK0188","LU2097828805.USD","BK0060","LU2580892862.HKD","LU1997244956.HKD","LU2328871848.SGD","LU0405327494.USD","LU1146622755.USD","BK0239"],"gpt_icon":0},{"id":"2592157528","title":"恒瑞医药：SHR-9539注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592157528","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592157528?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:11","pubTimestamp":1766135494,"startTime":"0","endTime":"0","summary":"南财智讯12月19日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司研发的SHR-9539注射液开展临床试验。审批结论显示，同意开展SHR-9539联合治疗在多发性骨髓瘤中的IB/II期研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596828474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1146622755.USD","LU1820825898.SGD","LU0405327494.USD","BK0060","BK0188","LU2097828474.EUR","LU2543165471.USD","LU1255011170.USD","LU1064131003.USD","LU2289578879.USD","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU2097828714.EUR","LU0359202008.SGD","01276","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU2097828805.USD","BK0183","LU0359201612.USD","LU2495084118.USD","LU1969619763.USD","BK0028","LU2097828631.EUR","BK0239","BK0012","LU1023057109.AUD","BK1191","LU2097828557.USD","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU1997245094.SGD","LU1580142542.USD","LU1655091616.SGD","LU2148510915.USD","600276","LU2488822045.USD","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2591264877","title":"小摩增持恒瑞医药(01276)387.9413万股 每股作价72.5974港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264877","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264877?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:59","pubTimestamp":1765796342,"startTime":"0","endTime":"0","summary":"增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1997244956.HKD","LU0942090050.USD","600276","LU0868494617.USD","BK4207","LU1146622755.USD","LU1997245177.USD","LU2592432038.USD","BK0012","01276","IE00BN8TJ469.HKD","BK4550","LU1551013342.USD","LU1244550494.USD","LU0964807845.USD","LU0345769128.USD","LU0405327148.USD","LU1064130708.USD","LU2417539215.USD","LU1551013425.SGD","LU2552382058.USD","BK4566","IE00BJTD4N35.SGD","LU0359202008.SGD","LU0820561818.USD","LU1366192091.USD","IE00BKVL7J92.USD","LU0496365809.HKD","LU1988902786.USD","BK4585","LU0405327494.USD","LU0170899867.USD","LU2462157665.USD","LU2237443895.HKD","IE00BFXG1179.USD","LU0267386448.USD","BK4588","LU0211326755.USD","LU1116320737.USD","BK4504","LU0048584097.USD","LU2456880835.USD","LU2756315664.SGD","LU0211328371.USD","IE00BJLML261.HKD","LU2213496289.HKD","LU2495084118.USD","LU2552382215.SGD","IE00BKDWB100.SGD","LU2097828805.USD"],"gpt_icon":0},{"id":"1170772367","title":"摩根大通在江苏恒瑞医药H股的多头头寸于12月9日从6.79%增至8.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170772367","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170772367?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:22","pubTimestamp":1765790560,"startTime":"0","endTime":"0","summary":"摩根大通在江苏恒瑞医药的H股多头头寸于12月9日从6.79%增加至8.29%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU2097828714.EUR","BK0012","LU1997245094.SGD","LU1997245177.USD","LU2097828474.EUR","LU2488822045.USD","LU2148510915.USD","LU1064130708.USD","LU2495084118.USD","LU2097828805.USD","LU2328871848.SGD","LU1580142542.USD","600276","BK0239","LU1064131003.USD","LU2580892789.USD","LU1146622755.USD","LU2580892862.HKD","BK0196","LU1655091616.SGD","LU1328615791.USD","BK0028","LU1781817850.SGD","LU2097828631.EUR","LU1255011170.USD","BK0188","LU1820825898.SGD","LU2097828557.USD","LU1969619763.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2591970396","title":"恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》","url":"https://stock-news.laohu8.com/highlight/detail?id=2591970396","media":"新浪科技","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591970396?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:59","pubTimestamp":1765778340,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》 ，这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。在HRD阳性人群，FZOCUS-1研究证实PARP抑制剂单药运用即可实现理想疗效，避免联合用药带来的副作用与经济负担。　　“FZOCUS-1研究全文在《CA》的成功发表，是中国临床肿瘤学研究的重要里程碑。”","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","LU2580892789.USD","BK0183","LU2328871848.SGD","BK0196","LU2097828631.EUR","LU1146622755.USD","LU2488822045.USD","LU0405327148.USD","BK0012","LU0359201612.USD","LU1781817850.SGD","LU1997245094.SGD","LU2097828474.EUR","LU0359202008.SGD","LU2097828714.EUR","LU2097828805.USD","BK0060","LU1580142542.USD","LU1655091616.SGD","LU1820825898.SGD","LU1997245177.USD","LU1064130708.USD","LU2543165471.USD","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","600276","LU0405327494.USD","BK0028","LU1255011170.USD","BK0239","LU1023057109.AUD","LU1997244956.HKD","LU2097828557.USD","LU0359201885.HKD","LU2495084118.USD","LU1969619763.USD","BK1191","LU1328615791.USD","LU2289578879.USD","01276","CA"],"gpt_icon":1},{"id":"2591699288","title":"国信证券：FXI抑制剂有望成为下一代抗凝药物 建议关注恒瑞医药(600276.SH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591699288","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591699288?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:41","pubTimestamp":1765766465,"startTime":"0","endTime":"0","summary":"建议关注恒瑞医药：FXI单抗SHR-2004进入3期临床，在国产分子中领先;并关注拥有FXI小核酸药物管线的公司。国信证券主要观点如下：FXI/FXIa抑制剂有望成为安全性更优的抗凝药物现有抗凝血药物均作用于凝血的共同通路，FXI仅参与内源性凝血通路以及血栓的正反馈放大，抑制FXI活性有望在抗凝血的同时减少出血的风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","LU1328615791.USD","BK0239","LU1655091616.SGD","LU2097828714.EUR","LU1146622755.USD","002736","LU1997244956.HKD","LU1997245094.SGD","LU2097828631.EUR","LU0405327494.USD","LU1781817850.SGD","LU1023057109.AUD","LU1064131003.USD","BK0196","LU2148510915.USD","LU2580892862.HKD","LU1064130708.USD","LU2289578879.USD","LU2097828474.EUR","LU1997245177.USD","LU2097828557.USD","LU2495084118.USD","BK0188","LU2488822045.USD","BK0060","LU0359201885.HKD","BK0276","LU0405327148.USD","LU2580892789.USD","BK1191","BK0183","01276","LU2097828805.USD","LU2328871848.SGD","BK0028","600276","LU1969619763.USD","LU2543165471.USD","BK0012","LU1255011170.USD","LU1820825898.SGD","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767753698911,"stockEarnings":[{"period":"1week","weight":0.0479},{"period":"1month","weight":0.0234},{"period":"3month","weight":-0.1187},{"period":"6month","weight":0.0948},{"period":"1year","weight":0.4061},{"period":"ytd","weight":0.0586}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"397246人(较上一季度增加8.94%)","perCapita":"16058股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}